医学
急性呼吸窘迫综合征
偏肺病毒
入射(几何)
呼吸窘迫
内科学
呼吸系统
免疫学
呼吸道感染
肺
外科
光学
物理
作者
Thyyar M. Ravindranath,A Sanchez Gomez,Ilana Harwayne‐Gidansky,Thomas J. Connors,Nathan Neill,Bruce Levin,Joy Howell,Lisa Saiman,John Scott Baird
摘要
Abstract Objectives To study the incidence, risk factors, clinical course, and outcome of ARDS in children with HMP and RSV. Working Hypothesis We hypothesized that ARDS in children with HMP was similar in incidence, risk factors, clinical course, and outcomes to ARDS in children with RSV. Study Design Retrospective, observational study over 2 years. Patient‐Subject Selection Patients included were <18 years old with HMP or RSV detected from nasopharyngeal specimens by commercial reverse transcriptase polymerase chain reaction assay admitted to a study site. Methodology We described the incidence of ARDS within 1 week following the detection of HMP or RSV using recently developed Pediatric ARDS (PARDS) criteria. We also assessed risk factors, clinical course, and outcomes of children in the PICU with HMP or RSV and PARDS or non‐PARDS. Results We identified 57 patients with HMP and 161 patients with RSV: the proportions of patients with either virus who developed PARDS (HMP: 23%, RSV: 20%) and severe PARDS (HMP: 9%, RSV: 7%) were similar, as were the proportions of patients with acute (or acute‐on‐chronic) respiratory failure who developed PARDS (HMP: 41%, RSV: 31%). In a logistic regression model, risk factors associated with PARDS included neurologic comorbidity and PIM 3 probability of mortality, but not virus type. The risk factors, clinical course, and outcomes were similar for patients with PARDS associated with HMP and RSV. Conclusions About 1/3 of children with HMP or RSV and acute (or acute‐on‐chronic) respiratory failure developed PARDS. Children with either virus and a neurologic comorbidity or an increased PIM 3 probability of mortality were at increased risk for PARDS.
科研通智能强力驱动
Strongly Powered by AbleSci AI